Background: X22 is one of the imidazopyridine derivatives designed and synthesized in our laboratory. This compound showed excellent anti-inflammatory activity in LPS-stimulated macrophages. We previously investigated the biological activities of X22, including treatment of obesityrelated complications and retinal ischemia/reperfusion injury.
Methods: In the present study, a reliable, rapid, and simple UPLC method was first established and validated for quantitative analysis of X22 in rat plasma. Plasma samples were prepared by protein precipitation and separated on an ACQUITY HSS T3 column with a gradient mobile phase consisting of acetonitrile and water containing 0.1% TFA at a flow rate of 0.3 mL/min.
Results: Good linearity (R2>0.997) was achieved using weighted (1/x2) least-squares linear regression over a concentration range of 10 ng/mL to 1000 ng/mL with a lower limit of quantification of 10 ng/mL for X22. The average extraction recoveries were > 91.3 % for X22 and > 92.4 % for neohesperidin dihydrochalcone. The intra- and inter-precision values of the assay were both < 4.0 %.
Conclusion: This method was successfully applied to a pharmacokinetic study on rats after administration of single intravenous and oral doses of 20 and 80 mg/kg, respectively.
Keywords: UPLC, pharmacokinetics, rat plasma, bioavailability, benzimidazole, imidazopyridine.
Involvement of Leukotriene Pathway in the Pathogenesis of Ischemia- Reperfusion Injury and Septic and Non-Septic Shock
Current Vascular Pharmacology Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets From Brain Ischemia-Reperfusion Injury to Possible Sporadic Alzheimers Disease
Current Neurovascular Research Role of Translocator Protein in Renal Ischemia Reperfusion, Renal Preservation and Acute Kidney Injury
Current Molecular Medicine Manual Thrombectomy During Primary Coronary Intervention in Acute Myocardial Infarction: A Brief Review
Reviews on Recent Clinical Trials Role of Complement Properdin in Renal Ischemia-Reperfusion Injury
Current Gene Therapy Selenium and Cardiovascular Surgery: An Overview
Current Drug Safety The Role of Thiols in Liver Ischemia-Reperfusion Injury
Current Pharmaceutical Design Ghrelin and Cardiovascular Diseases
Current Cardiology Reviews Wip1-Deficient Neutrophils Significantly Promote Intestinal Ischemia/Reperfusion Injury in Mice
Current Molecular Medicine Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetic Polymorphisms of Type-1 and Type-2 Inflammatory Cytokines in Ischaemic Stroke
Vascular Disease Prevention Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology A Novel Danshensu-Tetramethylpyrazine Conjugate DT-018 Provides Cardioprotection by Preserving Mitochondrial Function Through the MEF2D/PGC-1α Pathway
Current Pharmaceutical Design Reactive Oxygen and Nitrogen Species in the Renal Ischemia/Reperfusion Injury
Current Pharmaceutical Design Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design The Role of Macrophage Migration Inhibitory Factor in Critical Illness
Mini-Reviews in Medicinal Chemistry The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry Sodium Proton Exchanger Inhibitor in Ischemia/Reperfusion Injury in the Heart Surgery: Controversy in Clinical Application
Letters in Drug Design & Discovery Redox Signaling Pathways Involved in Neuronal Ischemic Preconditioning